TWI810397B - 治療癌症之方法 - Google Patents

治療癌症之方法 Download PDF

Info

Publication number
TWI810397B
TWI810397B TW108140085A TW108140085A TWI810397B TW I810397 B TWI810397 B TW I810397B TW 108140085 A TW108140085 A TW 108140085A TW 108140085 A TW108140085 A TW 108140085A TW I810397 B TWI810397 B TW I810397B
Authority
TW
Taiwan
Prior art keywords
bfl
cancer
mcl
cdk9
azd4573
Prior art date
Application number
TW108140085A
Other languages
English (en)
Chinese (zh)
Other versions
TW202033192A (zh
Inventor
賈斯汀 斯達多
史考特 波柯
麗莎 左錄
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202033192A publication Critical patent/TW202033192A/zh
Application granted granted Critical
Publication of TWI810397B publication Critical patent/TWI810397B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW108140085A 2018-11-14 2019-11-05 治療癌症之方法 TWI810397B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767215P 2018-11-14 2018-11-14
US62/767,215 2018-11-14

Publications (2)

Publication Number Publication Date
TW202033192A TW202033192A (zh) 2020-09-16
TWI810397B true TWI810397B (zh) 2023-08-01

Family

ID=68583377

Family Applications (2)

Application Number Title Priority Date Filing Date
TW108140085A TWI810397B (zh) 2018-11-14 2019-11-05 治療癌症之方法
TW112104478A TW202344250A (zh) 2018-11-14 2019-11-05 治療癌症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112104478A TW202344250A (zh) 2018-11-14 2019-11-05 治療癌症之方法

Country Status (6)

Country Link
US (1) US20220008392A1 (enExample)
EP (1) EP3881075A1 (enExample)
JP (1) JP2022507218A (enExample)
CN (1) CN112997078A (enExample)
TW (2) TWI810397B (enExample)
WO (1) WO2020099470A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
IT202400003478A1 (it) * 2024-02-19 2025-08-19 Sbarro Health Res Organization Inc Cdk9 per uso nella determinazione della reattivita' di un tumore a un chemioterapico o per uso nel trattamento del cancro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016252609B2 (en) * 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
TR201909286T4 (tr) 2015-06-29 2019-07-22 Astrazeneca Ab CDK9 inhibitörleri olarak polisiklik amid türevleri.
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 W eiguo Xiang,et al. "MCL-1 inhibition in cancer treatment", OncoTargets and Therapy, 2018: 11, 7301–7314.

Also Published As

Publication number Publication date
TW202033192A (zh) 2020-09-16
US20220008392A1 (en) 2022-01-13
TW202344250A (zh) 2023-11-16
CN112997078A (zh) 2021-06-18
JP2022507218A (ja) 2022-01-18
WO2020099470A1 (en) 2020-05-22
EP3881075A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
Qin et al. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
US20230255962A1 (en) Combination of a btk inhibitor and an inhibitor of cdk9 to treat cancer
Mao et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
Weeks et al. Uracil–DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed
Bill et al. SAR405838: a novel and potent inhibitor of the MDM2: p53 axis for the treatment of dedifferentiated liposarcoma
Iyengar et al. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
CN103998935B (zh) Hsp90组合疗法
Gao et al. Overexpression of CRM1: a characteristic feature in a transformed phenotype of lung carcinogenesis and a molecular target for lung cancer adjuvant therapy
Zhao et al. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells
Zhou et al. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer
Brady et al. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor
Zheng et al. Tyrosine threonine kinase inhibition eliminates lung cancers by augmenting apoptosis and polyploidy
Henssen et al. Targeting tachykinin receptors in neuroblastoma
TW202344250A (zh) 治療癌症之方法
EP3471713A1 (en) Cancer treatment by simultaneous targeting energy metabolism and intracellular ph
US10697020B2 (en) MicroRNA-129 as a biomarker for colorectal cancer
Kitazono-Saitoh et al. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines
EP3787620A1 (en) Combinations for treating cancer
Ou et al. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
Agliano et al. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy
EA021951B1 (ru) Противораковая комбинация
Rosendahl et al. Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition
Samukawa et al. Systemically administered D-allose inhibits the tumor energy pathway and exerts synergistic effects with radiation
EP2204177A1 (en) Cancer marker and therapeutic agent for cancer
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees